ARTICLE | Clinical News
Corticotrophin-releasing factor data
July 1, 1996 7:00 AM UTC
NTII announced that Phase I/II testing of CRF reduced symptoms in 6 of 7 patients who received the longest duration of treatment with the factor. Symptoms assessed in the two open-label pilot trials included seizures, muscle weakness, loss of coordination, and double vision.
The factor was delivered by intermittent bolus injection intravenously, or by continuous infusion, for one, three, or seven days. The 7 patients receiving the seven-day treatment showed average improvement of 42 percent in their neurological exam scores (National Cancer Institute Neurological Exam), compared to baseline. ...